RBC Capital Initiates Agilent at Outperform with $153 Price Target

Key Facts

In a move reflecting optimism in the life sciences sector, RBC Capital initiated coverage on Agilent Technologies with an Outperform rating and a $153 price target. According to reports, analysts believe the stock is currently undervalued as it trades near its 52-week low. This bullish stance is driven by strong product momentum and the company's strategic exposure to the expanding drug manufacturing market.

This initiation comes as investors seek value in analytical instrument providers, following peer results from companies like Thermo Fisher Scientific that showed stabilizing healthcare demand. Compared to industry peers, RBC's price target represents a significant premium over current trading levels, reflecting confidence in margin recovery per market data. Previous earnings reports have also highlighted Agilent's resilience against global supply chain fluctuations.

Traders should closely watch Agilent's upcoming Q2 fiscal earnings, which analysts identified as a potential primary catalyst for the stock. Based on market data, Agilent (A) closed at stable levels on May 26, 2026, with investors also eyeing the FOMC Minutes scheduled for May 20, 2026, which could impact broader sentiment for growth-oriented and large-cap equities.